50 results about "Targeted metabolomics" patented technology

The invention discloses a plant lactobacillus. The plant lactobacillus has the characteristic of efficiently tolerating 30% (w / v) cistanche substrate. The invention also discloses a medicinal and edible composition consisting of 85 parts of cistanche deserticola, 5 parts of rehmannia, 5 parts of fructus alpiniae oxyphyllae and 5 parts of Chinese yam, the composition is fermented by using plant lactobacillus, and the cistanche deserticola fermentation liquor is prepared by adopting a multi-stage temperature fermentation process to ferment for 16 hours. A non-targeted metabonomics result shows that the phytobacterium plantarum activates an upstream channel for synthesis of phenylethanoid glycoside substances, and the abundance of forsythiaside B is increased by 133 times compared with that before fermentation. The fermentation liquor can achieve the functions of reproductive anti-aging, kidney protection and body endurance improvement by down-regulating COX-2a and TGF-beta-1 gene expression.

The invention belongs to the technical field of biological medicine, and particularly relates to application of phenylalanine in evaluating Kawasaki disease and treating effect thereof and application of a phenylalanine inhibitor in treating Kawasaki disease. According to serum non-targeted metabonomics analysis and verification of KD children and IVIG treated KD children, phenylalanine is highly expressed in KD children, and phenylalanine is remarkably reduced after IVIG treatment of KD and tends to healthy children. The phenylalanine can be used as a serological marker for evaluating the Kawasaki disease treatment effect and diagnosing IVIG second-line treatment, and is high in specificity and sensitivity. After the phenylalanine inhibitor is administered to a KD model mouse, the content of phenylalanine in serum is remarkably reduced and is consistent with the trend in serum of the KD mouse treated by IVIG, myrica tongues are remarkably relieved, arterial dilatation is slowed down, and expression of inflammatory factors is reduced. The phenylalanine inhibitor has the effects of treating Kawasaki disease, improving myrica rubra tongue and slowing down arterial dilatation.

The invention discloses an application of astaxanthin in preparation of a regulator for improving the gentisic acid level. On the basis of non-targeted metabonomics analysis, it is found for the first time that in the SAP pathogenesis process, the level of a flora metabolite, namely gentisic acid (GA), in intestinal contents is remarkably reduced, and in-vivo gentisic acid level can be remarkably callback through astaxanthin intervention. Further research proves that exogenous supplement of gentisic acid can effectively simulate the protection effect of astaxanthin, including improvement of pancreatic tissue pathological damage, reduction of serum lipase and amylase activity, and inhibition of systemic inflammatory response (down-regulation of IL-1beta, IL-6 and TNF-alpha and up-regulation of IL-10). The invention not only discloses a new mechanism that astaxanthin plays a therapeutic role through an'intestinal flora-metabolite 'axis, but also determines that gentisic acid is used as a novel drug target for treating SAP, and constructs a new method for screening drugs for treating SAP according to the novel drug target.

The invention belongs to the technical field of compound analysis and identification, and discloses application of a metabonomics analysis technology to identification of lycium seed oil. According to the metabonomics analysis technology, the characteristic components of the lycium seed oil are identified through Log2 Fold Channel and VIP values, and the screening conditions for identifying the characteristic components of the lycium seed oil are | Log2 Fold Channel | > 1.5, and VIP < gt >; the method specifically comprises the steps of sample preparation, non-targeted metabonomics analysis, extraction and identification of characteristic peaks, similarity analysis, difference analysis and screening of differential markers. According to the method, a non-targeted metabonomics analysis method is adopted, various metabolic components in the lycium barbarum seed oil can be undiscriminately covered, the limitation that a traditional identification technology only aims at a few indexes is broken through, the unique characteristic components of the lycium barbarum seed oil can be accurately screened out, and the accuracy and specificity of an identification result are greatly improved.

The invention belongs to the technical field of drug detection, and particularly relates to a method for detecting lycium barbarum glycopeptide metabolites in rat plasma and tissues based on non-targeted metabonomics. According to the method, after rat lycium barbarum glycopeptides are administered through intragastric administration, blood, liver, intestine, lung and brain tissue samples after administration are collected. A UPLC-Q-TOF-MS (Ultra Performance Liquid Chromatography-Quadrupole Time of Flight Mass Spectrometry) analysis method is combined with a statistical analysis method comprising principal component analysis (PCA) and orthogonal-partial least squares discriminant analysis (OPLS-DA) to carry out in-vivo metabonomics analysis on the wolfberry glycopeptide. Then, based on a human metabolome database (HMDB), lycium barbarum glycopeptide differential metabolite is searched, so that the pharmacological action mechanism of the lycium barbarum glycopeptide is clarified from the perspective of metabolism, and a foundation is laid for deep research and development of the medicinal value of the lycium barbarum glycopeptide in future.

The application discloses a plant lactobacillus. The plant lactobacillus has the characteristics of high tolerance to 30% (w / v) cistanche matrix. The application also discloses a homologous medicinal and edible formula which is composed of 85 parts of cistanche, 5 parts of rehmannia root, 5 parts of yizhi kernel and 5 parts of yam. The formula is fermented by the plant lactobacillus, and a cistanche and yam fermented liquid is prepared by adopting a multi-stage temperature fermentation process for 16 hours. Non-targeted metabolomics results show that the plant lactobacillus activates the upstream pathway of phenylethanoid glycoside synthesis, and the abundance of forsythoside B is up-regulated by 133 times compared with that before fermentation. The fermented liquid can play the functions of reproductive anti-aging, kidney protection and body resistance improvement by down-regulating the expressions of COX-2a and TGF-beta-1 genes.

The invention discloses a drug collaborative screening system based on artificial intelligence prediction and metabonomics verification, and belongs to the technical field of artificial intelligence and bioinformatics crossing. Comprising a multi-source data acquisition and feature fusion module, an artificial intelligence prediction module, a drug screening and visualization module, a metabonomics verification module and a feedback optimization and self-learning module. According to the invention, through multi-modal data integration and feature coding, unified modeling of a drug-disease-molecule network is realized; drug combination synergistic effect prediction is realized through an artificial intelligence algorithm; a prediction result is verified by using non-targeted metabonomics data, and the mechanism interpretability of the model is enhanced; a technical system capable of realizing closed-loop optimization is constructed, and an algorithm and experiment dual-verification platform is provided for drug discovery and precision medicine.

The invention relates to the technical field of food identification, in particular to a method for identifying sheep milk and milk based on metabonomics, and aims to solve the industrial pain point that cheap milk is doped into current high-end sheep milk products and is difficult to detect through conventional physicochemical indexes, and the problems that existing protein, DNA and other identification methods are insufficient in sensitivity, complex in operation and the like. According to the invention, a non-targeted metabonomics analysis strategy is innovatively adopted. The saliency difference metabolites between the sheep milk and the milk are systematically screened from the omics level, and rapid, high-sensitivity and high-specificity identification on the authenticity of the sheep milk and whether the sheep milk is mixed with the milk is realized. According to the invention, a key technical basis and a material core are provided for developing corresponding detection products and market supervision methods.

This invention relates to a method for identifying and detecting urinary biomarkers of whole-grain wheat intake. These biomarkers include glycine conjugates of 3,5-dihydroxybenzoic acid, sulfate conjugates of o-aminophenol, sulfate conjugates of 2-acetaminophen, sulfate conjugates of 3,5-dihydroxyphenylvaleric acid, glucuronic acid conjugates of o-aminophenol, or glucuronic acid conjugates of 2-acetaminophen. The invention also relates to a high-throughput screening method for urinary biomarkers of whole-grain wheat intake. A whole-grain wheat dietary intervention experiment was designed, and through comparative analysis of human urinary metabolic profiles, non-targeted metabolomics technology was used to screen for urinary metabolic biomarkers of whole-grain wheat, providing a method for accurately assessing whole-grain wheat intake.

The application belongs to the technical field of biological medicine, and discloses application of NP in preparation of a preparation for regulating metabolism of the intestines of senile type 2 diabetes. The NP is formed by hydrogen bond combination of a peptide from soft-shelled turtle eggs with naringenin in a mass ratio of 100:1, and the mass of the peptide is less than 3 kDa; the preparation is used for regulating phenotype-related metabolic modules and intestinal micro-ecological-related metabolic modules, remodeling the intestinal metabolic regulation network taking differential metabolites as a bridge, and thus systemically improving metabolic disorders related to senile type 2 diabetes. It is found that NP intervention can obviously correct abnormal total metabolic profiles of feces of senile type 2 diabetes mice, and make the disease type metabolic profile shift to a new steady state of intervention type. Non-targeted metabolomics analysis by LC-MS / MS shows that the overall metabolic profile of the high-dose NP group is closer to that of the classic hypoglycemic drug metformin group, indicating that NP has a significant metabolic remodeling capacity.

The invention discloses an application of intestinal flora metabolite salicylic acid as a predictive marker of Escherichia coli calf diarrhea. The obviously up-regulated metabolite salicylic acid is screened out from the diarrhea calf feces through a non-targeted metabonomics technology, and in a group of new independent samples, it is verified through an ELISA test that the salicylic acid concentration of the diarrhea calf feces is obviously higher than that of a healthy group. ROC curve analysis shows that the area under curve (AUC) of SA for predicting escherichia coli calf diarrhea is 0.8148, and the method has good prediction capability. The invention provides a non-invasive, cheap, rapid and high-specificity prediction method, can be used for early warning and auxiliary diagnosis of Escherichia coli calf diarrhea, and has important significance for guiding clinical precise medication and reducing the death rate of calves.

This invention discloses a set of biomarkers, reagents, kits, and applications for predicting alcoholic liver disease (ALD), belonging to the field of biomarker technology. The key technical points are: This invention uses non-target metabolomics to analyze plasma from ALD patients and healthy controls to identify potential biomarkers and related metabolic pathways in the plasma of ALD patients. Through human fecal metagenomic sequencing, potential biomarkers in the microbiome of ALD patients are identified, providing a scientific basis for the pathogenesis and early screening of ALD. Furthermore, this invention evaluates the therapeutic effect of L-threonine on ALD and explores its molecular mechanism, providing solid preclinical evidence and theoretical basis for L-threonine as a safe and effective natural metabolite-derived drug for the treatment of ALD, opening new directions for the development of innovative ALD therapies.

The invention belongs to the technical field of biomedicine, and particularly relates to a method for detecting potential biomarkers of myocardial of an HFpEF mouse based on non-targeted metabonomics, which comprises the following steps: constructing an HFpEF mouse model by combining high fat diet with L-NAME, setting a conventional feeding control group, monitoring myocardial glucose metabolism through longitudinal [18F] FDG PET / CT, collecting myocardial tissues, and performing non-targeted metabonomics detection. And screening differential metabolites through Foldchange greater than or equal to 1.2 or less than or equal to 0.83 and p less than 0.05, and carrying out correlation analysis on the differential metabolites and [18F] FDG SUVmean to obtain 25 potential biomarkers. According to the method, the steps are clear and repeatable, the marker is directly related to myocardial energy metabolism, the diagnosis specificity is improved, and a support is provided for HFpEF targeted therapy research and development and molecular mechanism research.

The invention relates to the technical field of biomedicine, in particular to a group of key biomarkers for predicting endometrial receptivity, including specific microbial strains and metabolites, and a prediction model containing the markers. The method comprises the following steps: collecting a uterine cavity lavage fluid sample, carrying out 16S rRNA gene sequencing and non-targeted metabonomics analysis, and screening out eight key microbial strains and eight key metabolites; based on the markers, the following diagnostic models are constructed: a model only based on eight microbial strains; a model based on only eight metabolites; a combined microorganism and metabolite model; and a clinical data model is further combined. According to the method, a microbiome and metabolome multi-omics conjoint analysis strategy is adopted, strict screening is carried out in combination with LASSO regression, SVM-RFE and other machine learning algorithms, and the obtained biomarker is high in specificity. The constructed model, especially a combined model, shows high prediction precision and good calibration degree through verification of various curves.

The application discloses a kind of based on metabolic pathway analysis's Iresine heratensis fermentation quality regulation method, it is related to food biotechnology field, including, the sample of different varieties Iresine heratensis is obtained, carries out non-targeted metabolomics analysis, obtains metabolite spectrum data;The metabolite spectrum data carries out difference analysis, constructs key difference metabolite dataset;Metabolic pathway enrichment analysis is carried out to the key difference metabolite dataset, determines core metabolic pathway;Regulate the process parameter in Iresine heratensis fermentation process, obtain the fermentation product after regulation;The quality of the fermentation product after regulation is verified, feedback optimization the process parameter, form closed loop quality regulation method;The application is determined core metabolic pathway by constructing key difference metabolite dataset and enrichment analysis, realizes from traditional experience type fermentation process optimization to the change of accurate regulation based on metabolic mechanism, solves the problem that fermentation quality in prior art is greatly blind, target is not clear.

This invention belongs to the field of biomedical technology and discloses a bile acid-based predictive model for the severity of acute pancreatitis, its detection method, and its application. This invention establishes a combination of biomarkers that accurately reflect the pathological changes of acute pancreatitis by performing targeted metabolomics analysis on multiple small bile acid metabolites in serum, and further constructs a predictive model suitable for early clinical warning and severity stratification. This invention also provides a corresponding detection method for rapid and quantitative detection of the bile acid metabolites, enabling early identification and auxiliary diagnosis of severe acute pancreatitis.

The application discloses a construction method of a microbial-metabolite-host regulation network of summer South China calf based on Lactobacillus reuteri, and belongs to the technical field of microorganisms. The construction method comprises the following steps: collecting rumen, fecal sample and whole blood sample of the summer South China calf; obtaining microbial layer data through 16S rRNA sequencing, obtaining metabolite layer data through non-target metabolomics, and obtaining host gene / pathway layer data through whole blood transcriptomics; performing correlation analysis on multi-omics data to obtain a microbial-metabolite-host regulation correlation network. The regulation network significantly improves the growth performance of the summer South China calf, relieves diarrhea and enhances the digestive absorption function by improving the abundance of gastrointestinal beneficial bacteria, promoting the secretion of short-chain fatty acids and activating the host immune antioxidant pathway. The application realizes the precise mechanized application of probiotics by clarifying the regulation correlation among the three, and provides a mechanism-application integrated scheme for healthy breeding of calves.

The invention discloses a plasma metabolism biomarker combination for predicting and intervening propofol-induced respiratory depression, a detection method and application, and relates to the technical field of biological science. According to the method, non-target metabonomics detection is conducted on preoperative plasma of 298 subjects through UPLC-MS, 14-metabolite panels are obtained through machine learning supervised feature screening, a diagnosis model is established through verification of discovery and verification queues, and the prediction AUC of severe respiratory depression reaches 0.86-0.91 (discovery queue) and 0.86-0.91 (verification queue). Mouse in-vivo function verification proves that the key metabolite alpha-linolenic acid obviously improves the respiratory rate, the tidal volume and the minute ventilation volume under two administration paradigms of pretreatment and treatment of a mouse propofol-RD model, shortens the recovery time of righting reflex, has a good safety foundation, and has a good application prospect. Prompt can be converted into a foresight supplement or rapid treatment medication thought in a perioperative period, and a'prediction and intervention 'integrated clinical value is formed.

The invention discloses application of 2-hydroxycinnamic acid in treatment of gastric cancer, according to the application, the influence of supernate of lactobacillus salivarius or lactobacillus crispatus on gastric cancer cell apoptosis is detected through a flow technology, and the 2-hydroxycinnamic acid is found to be capable of promoting the gastric cancer cell apoptosis and inhibiting the activity of gastric cancer organs. A metabolite in a supernatant of lactobacillus salivarius CICC23175 or lactobacillus crispatus CGMCC1.2743 screened by non-target metabolite omics contains 2-hydroxycinnamic acid, and the gastric cancer cytotoxic resistance of 2-hydroxycinnamic acid is deeply studied to find that the 2-hydroxycinnamic acid not only has the effects of inhibiting gastric cancer cell proliferation, colony formation and cell migration, but also has the effects of inhibiting gastric cancer cell proliferation, colony formation and cell migration. In addition, the 2-hydroxycinnamic acid can also increase the proportion of cells in a G1 / G0 period of a cell cycle, promote apoptosis of gastric cancer cells, and find that the inhibition effect of the 2-hydroxycinnamic acid on proliferation of gastric cancer organs is integrally higher than that of normal gastric epithelium organs.

The invention relates to the technical field of agricultural microorganisms and fermentation engineering, and discloses a method for evaluating the growth promoting effect of saline-alkaline tolerant growth-promoting compound bacteria on soybeans, which comprises the following steps: preparing Klebsiella GF2 and pseudomonas GF7 through fermentation, compounding to form a GFM compound bacteria system, setting a saline-alkaline gradient pot experiment, combining rhizosphere inoculation and critical period supplementary application, and carrying out saline-alkaline tolerant growth-promoting compound bacteria on soybeans to obtain the saline-alkaline tolerant growth-promoting compound bacteria. The system monitors growth indexes of soybeans in the whole growth period and calculates comprehensive growth promoting indexes; high-throughput sequencing, fluorescence in situ hybridization and non-targeted metabonomics technologies are integrated, and a rhizosphere microbial community structure, functional bacterium colonization and a soil key metabolic pathway are analyzed; finally, multi-source data are coupled through multivariate statistics, the growth promoting contribution of the fungicide is quantified, and the stability of the cross-stress level of the fungicide is evaluated. A standardized evaluation system which is clear in mechanism and can be quantitatively compared is constructed, the blank of systematic evaluation of microbial agents in the saline-alkali environment is filled, and a key tool and theoretical support are provided for efficient strain screening and saline-alkali soil bioremediation technology popularization.

The present application relates to the field of biomedical technology, and particularly relates to a method for screening immune-related metabolites of a calf based on non-targeted metabolomics. The method comprises the following steps: S1. collecting peripheral blood of the calf at different time periods from birth to establishment of the immune system; S2. performing non-targeted metabolomics analysis on the peripheral blood samples at the different time periods to obtain differential metabolites at the different time periods; S3. annotating, clustering, performing enrichment analysis and performing overall change analysis of metabolic pathways on the differential metabolites at the different time periods screened out through a KEGG database to obtain key metabolites of the calf during establishment of the immune system and response mechanisms. The present application studies the expression change patterns of metabolic products of the calf before and after colostrum, understands the establishment process and response mechanisms of the immune system of the calf, and provides evidence and theoretical basis for when the passive immune system of the calf ends and how the immune system of the calf is regulated at the molecular level.

The invention discloses a marker group for screening and diagnosing sarcopenia and application, and belongs to the technical field of biological medicine. The marker group is composed of CCL13, FGF2, fatty acid amide and a proline derivative. The invention provides two sarcopenia high-sensitivity diagnosis combined models based on plasma multi-omics combined machine learning. Through an Olink Explore384 inflammation proteome platform and an LC-MS non-targeted metabolome technology, plasma samples of a sarcopenia patient and a healthy control person are subjected to systematic analysis, and differentially expressed proteins and metabolites are identified. Multiple machine learning algorithms are adopted to screen key features, and a single-omics and double-omics combined diagnosis model is constructed. The developed simplified diagnosis model only containing four core biomarkers shows excellent diagnosis performance (AUC gt, 0.9) in an independent verification queue, and has high clinical transformation value.

This invention belongs to the fields of bioinformatics and medical testing technology, specifically relating to a combination of biomarkers related to the postoperative prognosis of colorectal cancer and their application and prediction system. This invention, through 16S rRNA gene sequencing of tumor mucosal samples from colorectal cancer patients, combined with long-term postoperative follow-up data and screening, found that *Peptostreptococcus*, *Fusobacterium*, *Bacteroides*, *Porphyromonas*, and *Prevotella* are closely related to postoperative recurrence of colorectal cancer, with an AUC of 0.81 for assessing postoperative recurrence. Based on this, this invention conducts non-targeted metabolomics analysis, finding that combining alanine glutamate, putrescine, arginine, histidine, and sebacic acid with the above microbial biomarkers can improve the AUC to 0.91, significantly enhancing accuracy, specificity, and precision. This enables prognostic stratification of recurrence-free survival in colorectal cancer patients, demonstrating higher predictive efficacy and stability.

The application belongs to the field of biomedical technology, and aims to solve the problems of lack of metabolic typing characteristics in the current ESCC molecular typing method, lack of esophageal squamous cell carcinoma molecular typing method based on proteomics and metabolomics, and provides an esophageal squamous carcinoma ESCC molecular typing marker based on DIA proteomics and non-targeted metabolomics and its application. The marker is a combination of 4 proteins and 2 metabolites, the 4 proteins are: hexokinase 3 (HK3), Sec1 family domain protein 1 (SCFD1), septin 5 (SEPTIN5), and signal sequence receptor alpha subunit (SSR1); the 2 metabolites are creatine and 2-deoxy-D-glucose (2'DG). The application fills the gap of the molecular typing method based on proteomics and metabolomics in the field of esophageal squamous carcinoma research, and the proposed molecular typing model can be used as a method for diagnosis, treatment and prognosis evaluation of esophageal squamous carcinoma patients.

The invention discloses a method for detecting metabolite containing phosphate radicals, which is characterized in that a mass spectrum label with stable and characteristic chlorine isotope distribution is introduced through a chlorination reagent derivatization strategy, so that a derivatization product can be subjected to rapid and high-specificity preliminary identification based on primary mass spectrum data. By combining with an automatic data mining program specially developed for this purpose, high-throughput and accurate screening and locking of potential phosphate radical-containing metabolites from massive and complex non-targeted metabonomics original data are realized, and the data analysis efficiency and reliability are greatly improved. The method is successfully applied to analysis of actual biological samples such as cholestasis disease models, efficient identification and accurate quantification of various key metabolites such as nucleotide and sugar phosphoric acid are achieved, disturbance of related metabolic pathways is disclosed, and a powerful innovative analysis tool is provided for disease mechanism research and biomarker discovery.

This invention discloses a combination of metabolic biomarkers, identification methods, and applications for distinguishing between *Polygonum multiflorum* and its closely related species, *Polygonum chinense*. This invention employs ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS / MS) technology, integrating non-targeted metabolomics and statistical analysis (principal component analysis (PCA), sparse partial least squares discriminant analysis (SPLS-DA), and univariate analysis) to efficiently screen candidate biomarkers with identification potential, thereby achieving the identification of *Polygonum multiflorum* and its closely related species, *Polygonum chinense*.

The invention is applicable to the technical field of ginsenoside conversion, and provides application of organic acid in ginsenoside conversion, and the organic acid is lactic acid or acetic acid. According to the embodiment of the invention, from the perspective of the acid production variety and acid production content of the lactobacillus fermentum KP-3, the way and rule of converting ginsenoside and improving rare ginsenoside by the lactobacillus fermentum KP-3 are explored, and the change of organic acid in the fermentation process of the lactobacillus fermentum KP-3 is illuminated by adopting a targeted metabonomics method; according to the method, the influence of organic acid generated by lactobacillus fermentum KP-3 on ginsenoside change is analyzed, a ginsenoside conversion way and rule are defined, meanwhile, the oxidation resistance of fresh ginseng pulp is improved, and a theoretical basis is laid for development of ginseng healthy food.

The application relates to the field of biological medicine, and discloses application of piperidinic acid in preparation of a medicine for preventing and / or treating non-alcoholic steatohepatitis. The application first discovers that piperidinic acid can prevent and / or treat non-alcoholic steatohepatitis. Specifically, the application finds, through non-targeted metabolomics detection, that the content of piperidinic acid in fecal samples of NASH patients and mouse models is reduced, in-vivo experiments show that supplementing piperidinic acid can reduce the serum ALT and AST levels of NASH mice, reduce the content of triglyceride in the liver, and improve the degree of fatty degeneration, hepatocyte ballooning, inflammatory cell infiltration and fibrosis in the liver in histology. In-vitro experiments show that piperidinic acid can improve lipid deposition, inflammatory cell proliferation and fibrosis of liver organoids. Moreover, piperidinic acid is a metabolite of intestinal flora originally existing in a living body, has no obvious toxicity to the living body, is convenient and fast to administer through an oral mode, and can be conveniently obtained as a commercial reagent.

The invention belongs to the technical field of metabolite analysis, and particularly relates to a method for detecting polyphenol metabolite in tea based on full-targeted metabonomics. According to the method, the methanol aqueous solution is used for extraction, and the ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometer is used for detection, so that the method is simple and convenient to operate and high in extraction efficiency, methanol used in an extracting solution is a common reagent and is easy to obtain, separation is avoided in the extraction process, experimental errors are reduced, and the stability and repeatability of a detection result are ensured. Furthermore, according to the method, qualitative and quantitative analysis is carried out through mass spectrometry and a database, various data models (OPLS-DA, PLS-DA and the like) are established, the stability and repeatability of the whole analysis process are systematically evaluated, the polyphenol metabolites in various tea leaves are accurately analyzed, and a strong technical support is provided for standardization, precision and high-value development of the tea leaf industry.

The application discloses a biomarker of calcific aortic valve disease and application thereof, and belongs to the technical field of biological medicine. In the application, through non-targeted metabolomics discovery, serotonin deficiency can be a novel independent biomarker of calcific aortic valve stenosis. Specifically, receiver operating characteristic curve analysis shows that serotonin has good diagnostic efficiency for CAVD, and the optimal cutoff value is 148.2 ng / mL. Therefore, it is found in the application that the level of serotonin in CAVD patients is reduced, and the reduction is irrelevant to the severity of the disease, indicating that the serotonin has the potential to serve as a diagnostic biomarker.